These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Recombinant human tripeptidyl peptidase-1 infusion to the monkey CNS: safety, pharmacokinetics, and distribution. Vuillemenot BR; Kennedy D; Reed RP; Boyd RB; Butt MT; Musson DG; Keve S; Cahayag R; Tsuruda LS; O'Neill CA Toxicol Appl Pharmacol; 2014 May; 277(1):49-57. PubMed ID: 24642058 [TBL] [Abstract][Full Text] [Related]
12. First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy. Wawrzynski J; Martinez AR; Thompson DA; Ram D; Bowman R; Whiteley R; Gan C; Harding L; Mortensen A; Mills P; Gissen P; Henderson RH Eye (Lond); 2024 Apr; 38(6):1176-1182. PubMed ID: 38049626 [TBL] [Abstract][Full Text] [Related]
13. Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis. Vuillemenot BR; Katz ML; Coates JR; Kennedy D; Tiger P; Kanazono S; Lobel P; Sohar I; Xu S; Cahayag R; Keve S; Koren E; Bunting S; Tsuruda LS; O'Neill CA Mol Genet Metab; 2011 Nov; 104(3):325-37. PubMed ID: 21784683 [TBL] [Abstract][Full Text] [Related]
14. Retinal pathology in a canine model of late infantile neuronal ceroid lipofuscinosis. Katz ML; Coates JR; Cooper JJ; O'Brien DP; Jeong M; Narfström K Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2686-95. PubMed ID: 18344450 [TBL] [Abstract][Full Text] [Related]
15. Intraventricular Cerliponase Alfa Treatment in a Patient with Advanced Neuronal Ceroid Lipofuscinosis Type 2. Nakashima S; Hamada M; Kimura T; Tanifuji S; Takahashi A; Yashita D; Kakimoto Y; Matsukawa T; Ishiura H; Toda T Intern Med; 2024 Jun; 63(12):1807-1812. PubMed ID: 37926545 [TBL] [Abstract][Full Text] [Related]
16. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis. Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878 [TBL] [Abstract][Full Text] [Related]
17. Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis. Xu S; Wang L; El-Banna M; Sohar I; Sleat DE; Lobel P Mol Ther; 2011 Oct; 19(10):1842-8. PubMed ID: 21730969 [TBL] [Abstract][Full Text] [Related]
18. A reversal learning task detects cognitive deficits in a Dachshund model of late-infantile neuronal ceroid lipofuscinosis. Sanders DN; Kanazono S; Wininger FA; Whiting RE; Flournoy CA; Coates JR; Castaner LJ; O'Brien DP; Katz ML Genes Brain Behav; 2011 Oct; 10(7):798-804. PubMed ID: 21745338 [TBL] [Abstract][Full Text] [Related]
19. Neurofilament light is a treatment-responsive biomarker in CLN2 disease. Ru Y; Corado C; Soon RK; Melton AC; Harris A; Yu GK; Pryer N; Sinclair JR; Katz ML; Ajayi T; Jacoby D; Russell CB; Chandriani S Ann Clin Transl Neurol; 2019 Dec; 6(12):2437-2447. PubMed ID: 31814335 [TBL] [Abstract][Full Text] [Related]